Ajay Vaidya
Advanced Heart Failure and Transplant Cardiology · Los Angeles, CANPI 1538459276
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Abiomed at 43.4% of the total. Reporting peaked in 2024 at $6,623 and has fallen 63.7% since, to $2,404 in 2025.
Across 122 payments — averaging $136.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$7K
- Abbott$3K
- Edwards Lifesciences$3K
- Novartis$2K
- Medtronic$280
- Ancora Heart, Inc.$251
- plus $665 from 8 others
Across 12 payments — averaging $22,314 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$223K
- AstraZeneca$44K
What the payments were for
- Consulting fees$5,06930%
- Speaking & faculty fees$3,60022%
- Travel & lodging$3432%
- Food & beverage$7,64846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 44 | $7,233 |
| Abbott | 40 | $3,182 |
| Edwards Lifesciences | 4 | $2,809 |
| Novartis | 12 | $2,240 |
| Medtronic(2 entities) | 3 | $280 |
| Ancora Heart, Inc. | 7 | $251 |
| Impulse Dynamics (USA) Inc. | 3 | $213 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $194 |
| Mallinckrodt Hospital Products Inc. | 1 | $118 |
| Scpharmaceuticals Inc. | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Cvrx, Inc. | 1 | $31 |
| AstraZeneca | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$4,858
- CARDIOMEMS$1,124
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$818
- OPTIMIZER$291
- HeartWare HVAD$220
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$186
- UVADEX$118
How this compares
$16,660 in reported general payments places this provider in the 60th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 31 | $40,795 |
| Tacrolimus | 23 | $6,029 |
| Rosuvastatin Calcium | 21 | $644 |
| Atorvastatin Calcium | 21 | $295 |
| Carvedilol | 17 | $172 |
| Warfarin Sodium | 21 | $151 |
| Metoprolol Succinate | 13 | $140 |
| Spironolactone | 18 | $131 |
| Prednisone | 11 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,240 | $40,79531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Los Angeles
- Eugene DepasqualeLos Angeles$104K
- Joseph RahmanLos Angeles$101K
- Jon KobashigawaLos Angeles$54K
- Aaron WolfsonLos Angeles$16K
- Michael FongLos Angeles$9K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.